These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 7746816)
41. Nasal potential measurements on the nasal floor and under the inferior turbinate: does it matter? Vermeulen F; Proesmans M; Feyaerts N; De Boeck K Pediatr Pulmonol; 2011 Feb; 46(2):145-52. PubMed ID: 20865746 [TBL] [Abstract][Full Text] [Related]
43. Use of in vivo nasal transepithelial potential difference to evaluate efficacy in CF gene therapy phase I trials. Chinet TC Eur Respir J; 1994 Nov; 7(11):1917-20. PubMed ID: 7875259 [No Abstract] [Full Text] [Related]
44. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. Rubenstein RC; Egan ME; Zeitlin PL J Clin Invest; 1997 Nov; 100(10):2457-65. PubMed ID: 9366560 [TBL] [Abstract][Full Text] [Related]
45. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Knowles MR; Noone PG; Hohneker K; Johnson LG; Boucher RC; Efthimiou J; Crawford C; Brown R; Schwartzbach C; Pearlman R Hum Gene Ther; 1998 Jan; 9(2):249-69. PubMed ID: 9472784 [TBL] [Abstract][Full Text] [Related]
46. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. Knowles MR; Hohneker KW; Zhou Z; Olsen JC; Noah TL; Hu PC; Leigh MW; Engelhardt JF; Edwards LJ; Jones KR N Engl J Med; 1995 Sep; 333(13):823-31. PubMed ID: 7544439 [TBL] [Abstract][Full Text] [Related]
47. Nasal potential difference in cystic fibrosis diagnosis of very young children. Sermet-Gaudelus I; Girodon E; Huet F; Aboutaam R; Bui S; Deneuville E; Guillot M; Vrielynck S; Lenoir G; Edelman A J Pediatr; 2007 Mar; 150(3):e34-5. PubMed ID: 17307527 [No Abstract] [Full Text] [Related]
48. A new device for in vivo measurement of nasal transepithelial potential difference in cystic fibrosis patients and normal subjects. Duperrex O; Berclaz PY; Bertrand D; Lacroix JS; Pochon N; Belli D; Rochat T Eur Respir J; 1997 Jul; 10(7):1631-6. PubMed ID: 9230258 [TBL] [Abstract][Full Text] [Related]
49. Measurement of nasal potential difference in adult cystic fibrosis, Young's syndrome, and bronchiectasis. Alton EW; Hay JG; Munro C; Geddes DM Thorax; 1987 Oct; 42(10):815-7. PubMed ID: 3424257 [TBL] [Abstract][Full Text] [Related]
50. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Hofmann T; Stutts MJ; Ziersch A; Rückes C; Weber WM; Knowles MR; Lindemann H; Boucher RC Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1844-9. PubMed ID: 9620916 [TBL] [Abstract][Full Text] [Related]
52. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Sermet-Gaudelus I; Girodon E; Sands D; Stremmler N; Vavrova V; Deneuville E; Reix P; Bui S; Huet F; Lebourgeois M; Munck A; Iron A; Skalicka V; Bienvenu T; Roussel D; Lenoir G; Bellon G; Sarles J; Macek M; Roussey M; Fajac I; Edelman A Am J Respir Crit Care Med; 2010 Oct; 182(7):929-36. PubMed ID: 20538955 [TBL] [Abstract][Full Text] [Related]
53. The effect of N-acetyl-cysteine (Mucosolvin) on the transmural potential difference of the mucosa in children. Ballke EH; Wiersbitzky S; Mahner B; König A Padiatr Grenzgeb; 1992; 31(2):97-101. PubMed ID: 1305285 [TBL] [Abstract][Full Text] [Related]
54. Improved repeatability of nasal potential difference with a larger surface catheter. Vermeulen F; Proesmans M; Boon M; De Boeck K J Cyst Fibros; 2015 May; 14(3):317-23. PubMed ID: 25439742 [TBL] [Abstract][Full Text] [Related]
56. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Wilschanski M; Famini C; Blau H; Rivlin J; Augarten A; Avital A; Kerem B; Kerem E Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):860-5. PubMed ID: 10712334 [TBL] [Abstract][Full Text] [Related]
57. Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis? Ooi CY; Dupuis A; Gonska T; Ellis L; Ni A; Jarvi K; Martin S; Ray P; Steele L; Kortan P; Dorfman R; Solomon M; Zielenski J; Corey M; Tullis E; Durie P Ann Am Thorac Soc; 2014 May; 11(4):562-70. PubMed ID: 24697796 [TBL] [Abstract][Full Text] [Related]
58. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. McLachlan G; Ho LP; Davidson-Smith H; Samways J; Davidson H; Stevenson BJ; Carothers AD; Alton EW; Middleton PG; Smith SN; Kallmeyer G; Michaelis U; Seeber S; Naujoks K; Greening AP; Innes JA; Dorin JR; Porteous DJ Gene Ther; 1996 Dec; 3(12):1113-23. PubMed ID: 8986438 [TBL] [Abstract][Full Text] [Related]
59. Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients. Fajac I; Hubert D; Guillemot D; Honoré I; Bienvenu T; Volter F; Dall'Ava-Santucci J; Dusser DJ Thorax; 2004 Nov; 59(11):971-6. PubMed ID: 15516474 [TBL] [Abstract][Full Text] [Related]